Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00412581
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
- Target Recruit Count
- 642
- Registration Number
- NCT00410631
- Locations
- 🇩🇪
Kinderklinik - Universitaetsklinikum Aachen, Aachen, Germany
🇩🇪Klinikum Dortmund, Dortmund, Germany
🇩🇪Kliniken der Stadt Koeln gGmbH - Kinderkrankenhaus Riehl, Cologne, Germany
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Vical
- Target Recruit Count
- 390
- Registration Number
- NCT00395070
- Locations
- 🇺🇸
Location #23, Cleveland, Ohio, United States
🇺🇸Location #117, Houston, Texas, United States
🇺🇸Location #32, Seattle, Washington, United States
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2018-08-27
- Target Recruit Count
- 51
- Registration Number
- NCT00369681
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- AmpliMed Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT00327600
- Locations
- 🇺🇸
University of CO Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Investigational Site 012, Salt Lake City, Utah, United States
🇺🇸US Oncology Greenville, Cancer Centers of the Carolinas, Greenville, South Carolina, United States
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 681
- Registration Number
- NCT00324155
- Locations
- 🇺🇸
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸St Joseph Oncology Inc, Saint Joseph, Missouri, United States
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 27
- Registration Number
- NCT00308607
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital, Oulu, Finland
🇫🇮Tampere University Hospital, Tampere, Finland
HD11 for Intermediate Stages
- Conditions
- Hodgkin´s Lymphoma
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
HD10 for Early Stages
- Conditions
- Hodgkin´s Lymphoma
- Interventions
- Radiation: 20 Gy IF-RTRadiation: 30 Gy IF-RT
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1370
- Registration Number
- NCT00265018
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 655
- Registration Number
- NCT00257205
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.